AVJ16

AVJ16 is a potent and specific small molecule inhibitor of the insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1). IGF2BP1 regulates the stability, localization, and translation of various mRNA targets, and its overexpression is associated with poor clinical outcomes in multiple cancer types. AVJ16 was developed through structure-based optimization of an earlier lead compound (7773) identified via high-throughput screening. It binds directly to a hydrophobic region at the KH34 di-domain interface between the KH3 and KH4 domains of IGF2BP1, exhibiting a 12-fold higher binding efficiency than its predecessor. In preclinical studies, AVJ16 effectively inhibited cancer cell migration in cell lines with high endogenous IGF2BP1 expression but had no effect on cells lacking this protein, demonstrating target specificity. The drug is being investigated as a potential therapeutic agent for cancers that overexpress IGF2BP1[2][4][6][7].

Other names

2775241-92-2